SEC Form 4 · accession 0001209191-17-029237

NEOGENOMICS INC · NEO

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — Chairman and CEO

Period of report

Apr 28, 2017

Accepted (ET)

May 2, 2017 · 4:50 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001077183

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock^F1	holding	—	—		—	187,500	I	Conundrum Capital Partners
Common Stock^F2	holding	—	—		—	1,832,985	D

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Stock Option (Right to Buy)^F4	$7.52	Apr 28, 2017	A	500,000	A	Apr 28, 2018	Apr 28, 2022	Common Stock	500,000	500,000	D
Stock Option (Right to Buy)^F3	$7.15	holding	—	—	—	Apr 20, 2017	Apr 20, 2021	Common Stock	472,527	472,527	D

F1Conundrum Capital Partners, LLC is a limited liability partnership 50% owned by Mr. VanOort. Mr. VanOort is a managing partner of Conundrum Capital Partners, LLC
F2Includes 125,000 shares of restricted stock that the Board of Directors approved and granted on April 15, 2014. The terms of the award call for the stock to vest on the third anniversary of the grant date as long as Mr. Van Oort is still an employee of the Company. This was disclosed in our Quarterly Report on Form 10-Q as filed with the Securities and Exchange Commission on July 29, 2014.
F3On April 20, 2016, Mr. VanOort was granted 472,527 stock options. These options vest ratably over the first three anniversary dates of the grant date.
F4On April 28, 2017, Mr. VanOort was granted 500,000 stock options. These options vest ratably over the first three anniversary dates of the grant date.